AU2004266063B2 - Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease - Google Patents

Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease Download PDF

Info

Publication number
AU2004266063B2
AU2004266063B2 AU2004266063A AU2004266063A AU2004266063B2 AU 2004266063 B2 AU2004266063 B2 AU 2004266063B2 AU 2004266063 A AU2004266063 A AU 2004266063A AU 2004266063 A AU2004266063 A AU 2004266063A AU 2004266063 B2 AU2004266063 B2 AU 2004266063B2
Authority
AU
Australia
Prior art keywords
pharmaceutical preparation
preparation according
combination
active substance
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004266063A
Other languages
English (en)
Other versions
AU2004266063A1 (en
Inventor
Michael Horstmann
Frank Theobald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LTS Lohmann Therapie Systeme AG
Original Assignee
LTS Lohmann Therapie Systeme AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34201721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004266063(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by LTS Lohmann Therapie Systeme AG filed Critical LTS Lohmann Therapie Systeme AG
Publication of AU2004266063A1 publication Critical patent/AU2004266063A1/en
Application granted granted Critical
Publication of AU2004266063B2 publication Critical patent/AU2004266063B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2004266063A 2003-08-20 2004-08-14 Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease Ceased AU2004266063B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10338174A DE10338174A1 (de) 2003-08-20 2003-08-20 Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
DE10338174.0 2003-08-20
PCT/EP2004/009136 WO2005018619A1 (de) 2003-08-20 2004-08-14 Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit

Publications (2)

Publication Number Publication Date
AU2004266063A1 AU2004266063A1 (en) 2005-03-03
AU2004266063B2 true AU2004266063B2 (en) 2010-04-08

Family

ID=34201721

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004266063A Ceased AU2004266063B2 (en) 2003-08-20 2004-08-14 Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease

Country Status (21)

Country Link
US (1) US8980308B2 (https=)
EP (1) EP1656122B2 (https=)
JP (2) JP2007502795A (https=)
KR (1) KR20060065692A (https=)
CN (1) CN1832732A (https=)
AT (1) ATE446744T1 (https=)
AU (1) AU2004266063B2 (https=)
BR (1) BRPI0412054A (https=)
CA (1) CA2535063C (https=)
DE (2) DE10338174A1 (https=)
DK (1) DK1656122T4 (https=)
ES (1) ES2335771T5 (https=)
IL (1) IL173712A (https=)
MX (1) MXPA06001815A (https=)
NZ (1) NZ545593A (https=)
PL (1) PL1656122T5 (https=)
PT (1) PT1656122E (https=)
RU (1) RU2397757C2 (https=)
SI (1) SI1656122T2 (https=)
WO (1) WO2005018619A1 (https=)
ZA (1) ZA200509779B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
AU2005284908B2 (en) 2004-09-13 2011-12-08 Morningside Venture Investments Limited Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
PL1907382T3 (pl) 2005-07-26 2016-01-29 Bial Portela & Ca Sa Pochodne nitrokatecholowe jako inhibitory COMT
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
BRPI0721213B1 (pt) 2007-01-31 2021-11-09 Bial - Portela & Ca, S.A. Uso de nitrocatecóis substituídos, e embalagem
RU2326660C1 (ru) * 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
CN103977003A (zh) 2007-04-02 2014-08-13 帕金森氏病研究院 用于降低治疗的副作用的方法和组合物
US20100092554A1 (en) * 2007-04-24 2010-04-15 Boehringer Ingelheim International Gmbh Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
ES2723729T3 (es) * 2008-07-29 2019-08-30 Bial Portela & Ca Sa Régimen de administración de nitrocatecoles
PT2413912T (pt) 2009-04-01 2019-06-11 Bial Portela & Ca Sa Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir
KR101292768B1 (ko) * 2010-04-23 2013-08-05 아이큐어 주식회사 경피 흡수 제제
ES2608782T3 (es) 2010-04-30 2017-04-17 Teikoku Pharma Usa, Inc. Composiciones transdérmicas de propinilaminoindano
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
EP2688561B1 (en) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
WO2013006643A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
JP6456143B2 (ja) 2011-12-13 2019-01-23 ノヴィファーマ，エス．アー． カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
US20130197023A1 (en) * 2012-01-27 2013-08-01 California Institute Of Technology Neuroprotection by pharmacological chaperoning of nicotinic acetylcholine receptors
AU2013338243B2 (en) 2012-11-02 2016-09-29 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
WO2014210544A2 (en) 2013-06-27 2014-12-31 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
CN103622997A (zh) * 2013-11-22 2014-03-12 内蒙古医科大学 包含谷氨酸受体阻断剂盐酸美金刚或其药学可接受的盐与β受体阻断剂的药物组合物
EP2946775A1 (de) 2014-05-20 2015-11-25 LTS LOHMANN Therapie-Systeme AG Lavendelöl enthaltendes transdermales therapeutisches System
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
CN104510725B (zh) * 2015-01-22 2021-04-27 中国药科大学 一种普拉克索周效透皮贴剂及其制备方法
AU2016211330A1 (en) 2015-01-28 2017-08-03 Chrono Therapeutics Inc. Drug delivery methods and systems
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
CN114668747A (zh) * 2016-10-07 2022-06-28 全崴生技股份有限公司 普拉克索经皮贴片系统与用法
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
US20240299501A1 (en) * 2023-03-06 2024-09-12 Xygenyx Inc. Composition and methods of treatment using transdermal hormone supplementation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009051A1 (en) * 1988-03-29 1989-10-05 Sandoz Ag Deprenyl for systemic transdermal administration
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
FR2788982A1 (fr) * 1999-02-02 2000-08-04 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
WO2002047666A1 (de) * 2000-12-16 2002-06-20 Neurobiotec Gmbh Verwendung eines dopaminagonisten mit kurzer halbwertszeit zur behandlung von dopaminerg behandelbaren erkrankungen

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
JPH0611698B2 (ja) 1984-12-19 1994-02-16 大正製薬株式会社 貼付剤
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
DE3764144D1 (de) 1986-04-16 1990-09-13 Asta Pharma Ag Synergistische kombination von amantadin und selegilin.
DE3710966A1 (de) 1986-04-16 1987-12-03 Degussa Synergistische kombination von amantadin und selegilin
US4877618A (en) * 1988-03-18 1989-10-31 Reed Jr Fred D Transdermal drug delivery device
US4963568A (en) * 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
AU4673993A (en) * 1992-07-28 1994-02-14 Procter & Gamble Company, The Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether
DE4332094C2 (de) 1993-09-22 1995-09-07 Lohmann Therapie Syst Lts Lösemittelfrei herstellbares Wirkstoffpflaster und Verfahren zu seiner Herstellung
US5744476A (en) * 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
GB9511366D0 (en) 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
CA2223588C (en) 1995-06-07 2004-01-06 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
DE19626621A1 (de) 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
US5877173A (en) * 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
JPH11209271A (ja) 1998-01-23 1999-08-03 Nitto Denko Corp 経皮吸収製剤
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
CA2359640C (en) 1999-02-05 2008-11-18 Cipla Limited Topical sprays
WO2000074661A2 (en) 1999-06-05 2000-12-14 Noven Pharmaceuticals, Inc. Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
FR2798065B1 (fr) 1999-09-02 2003-09-05 Assist Publ Hopitaux De Paris Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
JP2002097137A (ja) 2000-07-19 2002-04-02 Junichi Sudo パーキンソン病の予防および／または治療剤
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
DE10043321B4 (de) 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
US20030119884A1 (en) * 2000-11-01 2003-06-26 Epstein Mel H. Methods and compositions for regulating memory consolidation
CA2381630A1 (en) 2001-04-23 2002-10-23 Leonard Theodore Meltzer Method for preventing dyskinesias
EP1256339B1 (en) 2001-05-08 2003-10-15 Schwarz Pharma Ag Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
ATE246919T1 (de) 2001-05-08 2003-08-15 Sanol Arznei Schwarz Gmbh Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009051A1 (en) * 1988-03-29 1989-10-05 Sandoz Ag Deprenyl for systemic transdermal administration
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
FR2788982A1 (fr) * 1999-02-02 2000-08-04 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
WO2002047666A1 (de) * 2000-12-16 2002-06-20 Neurobiotec Gmbh Verwendung eines dopaminagonisten mit kurzer halbwertszeit zur behandlung von dopaminerg behandelbaren erkrankungen

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MUCKE, H., Rotigotine Schwarz Pharma. Idrugs, Current Drugs Ltd, 2003, vol. 6, no. 9, pages 894-899 (Y) *
TUITE, P. et al., Expert Opinion on Investigational Drugs, 1 August 2003 vol. 12, no. 8, pages 1335-1352 (Y) *

Also Published As

Publication number Publication date
KR20060065692A (ko) 2006-06-14
AU2004266063A1 (en) 2005-03-03
JP2007502795A (ja) 2007-02-15
MXPA06001815A (es) 2006-05-31
ES2335771T3 (es) 2010-04-05
RU2005141214A (ru) 2006-07-27
JP2012092127A (ja) 2012-05-17
PL1656122T5 (pl) 2013-04-30
WO2005018619A1 (de) 2005-03-03
SI1656122T1 (sl) 2010-02-26
EP1656122B1 (de) 2009-10-28
NZ545593A (en) 2009-09-25
EP1656122B2 (de) 2012-11-28
EP1656122A1 (de) 2006-05-17
ES2335771T5 (es) 2013-03-26
PT1656122E (pt) 2010-02-02
SI1656122T2 (sl) 2013-03-29
CA2535063C (en) 2014-06-17
US20070026054A1 (en) 2007-02-01
DK1656122T4 (da) 2013-03-11
IL173712A (en) 2010-11-30
IL173712A0 (en) 2006-07-05
JP5827114B2 (ja) 2015-12-02
PL1656122T3 (pl) 2010-03-31
ATE446744T1 (de) 2009-11-15
US8980308B2 (en) 2015-03-17
RU2397757C2 (ru) 2010-08-27
BRPI0412054A (pt) 2006-08-15
CN1832732A (zh) 2006-09-13
DK1656122T3 (da) 2010-03-08
CA2535063A1 (en) 2005-03-03
DE502004010303D1 (de) 2009-12-10
DE10338174A1 (de) 2005-03-24
ZA200509779B (en) 2006-09-27

Similar Documents

Publication Publication Date Title
AU2004266063B2 (en) Medicament preparations for transdermal application containing active ingredient combinations for treating parkinson's disease
US4818541A (en) Transdermal delivery of enantiomers of phenylpropanolamine
US20220395469A1 (en) Transdermal drug delivery system for ketamine
KR101725832B1 (ko) 경피 흡수형 제제
JP6301356B2 (ja) ロチゴチンの経皮投与のための複数日用のパッチ
JP5253707B2 (ja) レストレスレッグス症候群を処置するための経外角皮的投与形
JPH04503357A (ja) ニコチンの経皮デリバリー用デバイス
WO2008021113A2 (en) Transdermal methods and systems for treating alzheimer's disease
KR20060113638A (ko) 프라미펙솔 활성 제제를 함유하는 경피치료 시스템
TWI764173B (zh) 含羅替戈汀之貼附劑
JP2017519837A (ja) 経皮送達システム
JP2026009105A5 (https=)
EP3522843B1 (en) Pramipexole transdermal delivery system and uses thereof
CN101180018B (zh) 用于治疗恶心的经皮的方法和贴片
US20040081682A1 (en) Transdermal system (tds) that contain inhibitors of phosphodiesterase lV
JP2006045099A (ja) 経皮吸収貼付剤
CN116712413A (zh) 一种普拉克索透皮贴剂
CN117120095A (zh) 抑制结晶的罗替高汀透皮给药系统及其制备方法和用途
JP2025116972A (ja) 皮膚貼付用膏体組成物
HK40025664A (en) Transdermal drug delivery system for ketamine
JP2017007994A (ja) 経皮吸収型製剤

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired